Generic Name and Formulations:
Acrivastine 8mg, pseudoephedrine HCl 60mg; caps.
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Vitamin D May Not Reduce Head and Neck Cancer Risk
- Sorafenib May Improve Outcomes in Patients With FLT3-ITD AML Receiving allo-HSCT
Indications for SEMPREX-D:
Seasonal allergic rhinitis symptoms.
1 cap every 4–6 hours, max 4/day.
Severe hypertension or coronary artery disease. During or within 14 days of MAOIs.
Hypertension. Diabetes. Ischemic heart disease. Increased intraocular pressure. Hyperthyroidism. GI or GU obstruction. Elderly. Pregnancy (Cat.B). Renal impairment (CrCl ≤48mL/minute), nursing mothers: not recommended.
Hypertensive crisis with MAOIs. β-blockers may increase the pressor effects of sympathomimetics. Alcohol, other CNS depressants potentiated. Antagonizes antihypertensives.
Antihistamine + sympathomimetic.
Somnolence, dry mouth, nervousness, insomnia, ephedrine-like reactions (tachycardia, palpitations, headache, dizziness, nausea).
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma